Neurocrine Biosciences, Inc. (NBIX)
NBIX moved a median of -0.14% 30 minutes after news, and -0.16% by the close. How NBIX actually reacts to news — the realized, point-in-time move the market made, measured across 619 labeled events over the last three years with zero look-ahead.
NBIX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.07% | 44% | 615 |
| 30-min | -0.14% | 42% | 617 |
| 60-min | -0.10% | 48% | 617 |
| to close | -0.16% | 46% | 618 |
| Middle 50% of NBIX reactions | -0.60% to +0.38% |
|---|---|
| Median reaction (30-min) | -0.14% |
| Measured reactions | 619 |
Half of all Neurocrine Biosciences, Inc. news events land between -0.60% and +0.38% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NBIX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 32 | -0.03% | 50% | -0.30% |
| Analyst downgrades | 20 | +0.04% | 55% | -0.33% |
| Coverage initiations | 32 | +0.07% | 59% | +0.63% |
| Rating reiterations | 220 | +0.03% | 51% | -0.40% |
| Price-target raises | 108 | -0.11% | 43% | -0.54% |
| Price-target cuts | 34 | -0.10% | 41% | -0.29% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how NBIX ranks against every other measured name →
That’s how NBIX usually reacts — get an email when it moves on news →Email me when NBIX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NBIX's baseline. Nothing else.
Recent NBIX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Neurocrine Biosciences to Present at Upcoming Investor Conferences in September | Press release | PR Newswire | -0.56% | -0.99% | |
| Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia | Press release | PR Newswire | -1.53% | -2.04% | |
| Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist | Press release | PR Newswire | -0.93% | +1.16% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.66% | -9.52% | |
| Form 8-K/A NEUROCRINE BIOSCIENCES For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -1.67% | -0.76% | |
| Form S-8 NEUROCRINE BIOSCIENCES | SEC filing · Form S-8 | SEC EDGAR | -1.67% | -0.76% | |
| Form 8-K NEUROCRINE BIOSCIENCES For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -6.66% | -9.52% | |
| Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results | Press release | PR Newswire | -6.66% | -9.52% | |
| Neurocrine Biosciences Announces Key Leadership Hiring, Promotions | Press release | PR Newswire | +0.23% | +0.87% | |
| Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer | Press release | PR Newswire | -0.03% | -3.46% | |
| Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results | Press release | PR Newswire | -1.05% | -2.15% | |
| Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia | Press release | PR Newswire | -0.17% | +3.05% | |
| Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11ß-Hydroxylase Deficiency at ENDO 2026 | Press release | PR Newswire | -0.44% | -2.61% | |
| Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 | Press release | PR Newswire | -1.44% | -0.24% | |
| Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 | Press release | PR Newswire | -1.44% | -0.24% | |
| Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period | Press release | PR Newswire | -0.44% | -2.61% | |
| Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients | Press release | PR Newswire | +0.93% | +0.21% | |
| Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities | Press release | PR Newswire | -0.41% | -0.46% | |
| Neurocrine Biosciences to Present New Two-Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient-Reported Outcome Measures at ENDO 2026 | Press release | PR Newswire | +2.13% | +6.14% | |
| Form 8-K NEUROCRINE BIOSCIENCES For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -0.29% | +1.01% | |
| Neurocrine Biosciences to Present at Upcoming Investor Conferences in June | Press release | PR Newswire | -0.84% | -0.58% | |
| Form 8-K NEUROCRINE BIOSCIENCES For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.05% | -0.94% | |
| Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | Press release | PR Newswire | +0.05% | -0.94% | |
| Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | Press release | PR Newswire | -1.01% | -1.42% | |
| Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | Press release | PR Newswire | -1.68% | -1.20% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.68% | -1.20% | |
| Form 8-K NEUROCRINE BIOSCIENCES For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -1.68% | -1.20% | |
| Neurocrine Biosciences Reports First-Quarter 2026 Financial Results | Press release | PR Newswire | -1.68% | -1.20% | |
| Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 | Press release | PR Newswire | +0.50% | +0.04% | |
| Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist | Press release | PR Newswire | +0.61% | +1.74% | |
| Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment | Press release | PR Newswire | +0.61% | +1.74% | |
| Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia | Press release | PR Newswire | +0.61% | +1.74% | |
| Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale | Press release | PR Newswire | +0.27% | -0.28% | |
| Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia | Press release | PR Newswire | +0.26% | -0.76% | |
| Form ARS NEUROCRINE BIOSCIENCES For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.17% | -1.98% | |
| Form DEF 14A NEUROCRINE BIOSCIENCES For: Apr 15 | SEC filing · Form DEF | SEC EDGAR | +0.17% | -1.98% | |
| Form DEFA14A NEUROCRINE BIOSCIENCES | SEC filing · Form DEFA14A | SEC EDGAR | +0.17% | -1.98% | |
| Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results | Press release | PR Newswire | -0.38% | -0.39% | |
| Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR | Press release | PR Newswire | +1.35% | +3.55% | |
| Form 8-K NEUROCRINE BIOSCIENCES For: Apr 05 | SEC filing · Form 8-K | SEC EDGAR | -1.02% | +1.18% | |
| Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio | Press release | PR Newswire | -1.02% | +1.18% | |
| Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings | Press release | PR Newswire | -0.38% | +0.98% | |
| Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer | Press release | PR Newswire | -0.18% | +0.58% | |
| Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum | Press release | PR Newswire | +0.17% | -0.25% | |
| BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) | Press release | PR Newswire | +0.87% | +1.17% | |
| Neurocrine Biosciences to Present at Upcoming Investor Conferences in March | Press release | PR Newswire | -0.85% | -0.64% | |
| Form 10-K NEUROCRINE BIOSCIENCES For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.88% | -6.98% | |
| Form 8-K NEUROCRINE BIOSCIENCES For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -2.88% | -6.98% | |
| Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 | Press release | PR Newswire | -2.88% | -6.98% | |
| Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia | Press release | PR Newswire | +0.42% | +0.11% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NBIX section they belong to.
Where else NBIX is measured.
NBIX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CHINA BIOLOGIC PRODUCTS (CBPO) | 619 | -0.04% | 42% |
| INTELLIPHARMACEUTICS (IPCI) | 619 | -0.40% | 39% |
| Amgen Inc. (AMGN) | 618 | +0.12% | 59% |
| Jounce Therapeutics, Inc. (JNCE) | 612 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Neurocrine Biosciences, Inc.'s median reaction calculated?
Every labeled NBIX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 619 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of NBIX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does NBIX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.